Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Willow Biosciences Inc T.WLLW

Alternate Symbol(s):  CANSF

Willow Biosciences Inc. is a Canada-based biotechnology company. The Company develops and produces precision fermented functional ingredients for the health and wellness, food and beverage and personal care markets. Its FutureGrown biotechnology platform allows production with sustainability at its core. Its commercial product, Cannabigerol CBG, which is a cannabinoid that has anti-microbial, anti-inflammatory, and antioxidant properties. It also offers BioOxi, a bio-oxidation technology platform. By leveraging BioOxi, commercial partners can revolutionize manufacturing of oxygenated and hydroxylated functional ingredients, such as steroids, polyphenols, oxyterpenes and certain other targeted ingredients produced from such methods. It is also developing BioOxi-based process for production of the generic active pharmaceutical ingredient (API), hydrocortisone, and its derivatives. Its other pipeline products include Ursodeoxycholic acid (UCAC), Astaxanthin, B-carotene and others.


TSX:WLLW - Post by User

Post by jermiah777on Aug 14, 2021 3:28am
325 Views
Post# 33705710

Revenue estimates for willow

Revenue estimates for willowI found on markets.businessinsider.com when you look up Willow under CANSF, they have an analyst that gives Willow's future revenue and EBIT ( earnings before interest and taxes) I don't know how credible it is but here are the estimates they say For 2022 17 million revenue , 5.8 million EBIT Which if true is amazing. I am following another company that is projecting 100 million revenue but only 5 million EBIT Could Willow's margins be that favorable that almost 1/3 of revenue can be EBIT ? But 2023 estimate is even more extreme. 58 million ! If true that would be revenue more than tripling from 2022 And 24 million EBIT !!! THAT would be 4 times previous year. Man if this analyst's estimates are true then we have nothing to be concerned about. Willow has 40 million in cash and their burn rate can keep them going almost 2 years. But If they get earnings of 5.8 in 2022 and 24 million in 2023 then they will not even need the whole 40 million to get to profit.
<< Previous
Bullboard Posts
Next >>